Tam metin
我找的是 SIR-Sphere，他的適應症是肝癌的移轉，之 所以找他是因為健喬(4114)是他的製造商，此藥於 2011 年的第二季取得藥證，初期走的是自費市場，預 計半年以後會取得健保藥價給付，這產品在公司裡面 算是一個 star，預計與另外兩個新取得藥證 INNO-Mustin、HepaShere 的抗癌藥在 2012 可以貢獻 公司營收 1-1.2 億元(參考資料：公開資訊觀測站、投 顧)
這是專利檢所的部分，這次我查的是 Lasyn，一樣是 健喬的代工產品，他是專門用來降血脂肪的!
由於預計 2011 年ＥＰＳ=-0.22 元，虧損原因雖為轉 投資公司的虧損，但就算拿 2012EPS=0.89 來計算，今 (28)本益比高達 30 倍!故目前價格不建議購買。
Benzer Belgeler
高膽固醇飲食添加紅麴粉末 (Monascus Extract) 對倉鼠體內脂質代謝與血漿總抗氧化 能力之影響 謝孟志 1 、黃士懿 2 、錢 信 3 、楊惠婷 4
[r]
Secondary data analysis was carried out on the 712 subjects who were at least 50 years old and had reported having hypertension in order to assess the effects of demographic,
鈣離子阻斷器 脈優錠 (NORVASC) 達爾能持續性膠囊 (Diltelan) 合必爽錠 (Herbesser) 培爾吉平糖衣錠 (Perdipine) 壓達能軟膠囊
Efficacy analysis was the changes in blood pressure and number of patients meeting their goal blood pressure before and after therapeutic interchange.. Safety analysis was to
Efficacy analysis was the cha nges in blood pressure and number of patients meeting their goal blood pressure before and after therapeutic interchange.. Safe ty analysis was to
高血壓病患牙科就醫應注意的事項 返回 醫療衛教 發表醫師 發佈日期 2010/02 /18
symptoms before or after diagnosis were more likely to adhere to self management activities than those who were uncertain; (3) the findings of confirmatory factor analysis
